Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NERV
stocks logo

NERV

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
--
--
-0.350
-111.78%
--
--
-0.110
-80.36%
--
--
-0.140
-72%
Estimates Revision
The market is revising No Change the revenue expectations for Minerva Neurosciences, Inc. (NERV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 59.15%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+59.15%
In Past 3 Month
Wall Street analysts forecast NERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NERV is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast NERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NERV is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 3.740
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 3.740
sliders
Low
4.00
Averages
4.00
High
4.00
H.C. Wainwright
Neutral
downgrade
$5 -> $4
2025-11-06
Reason
H.C. Wainwright
Price Target
$5 -> $4
2025-11-06
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on Minerva to $4 from $5 and keeps a Neutral rating on the shares. The firm cites equity dilution for the target drop.
HC Wainwright & Co.
Douglas Tsao
Hold
Reiterates
$5
2025-02-26
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$5
2025-02-26
Reiterates
Hold
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Minerva Neurosciences Inc (NERV.O) is -6.68, compared to its 5-year average forward P/E of -1.89. For a more detailed relative valuation and DCF analysis to assess Minerva Neurosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.89
Current PE
-6.68
Overvalued PE
-0.40
Undervalued PE
-3.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
37.40
Current PS
0.00
Overvalued PS
153.15
Undervalued PS
-78.35
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

NERV News & Events

Events Timeline

(ET)
2025-12-01
15:20:00
Jefferies Raises Minerva Price Target to $5, Maintains Hold Rating
select
2025-11-05 (ET)
2025-11-05
07:32:28
Minerva announces Q3 earnings per share of 36 cents, down from $2.97 a year ago.
select
2025-10-21 (ET)
2025-10-21
08:13:57
Minerva reveals funding of up to $200M to progress roluperidone development.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
10-22TipRanks
Tuesday's Major Stock Market Highlights: Morning News Summary!

  • Stock Market News Overview: Tuesday features a wealth of stock market news that traders should monitor closely.

  • TipRanks Compilation: TipRanks has curated a list of the most significant stock market stories for today.

  • Importance for Traders: Staying updated on these stories is crucial for traders looking to make informed decisions.

  • Access to Full Stories: Readers can find all the top stock market stories by visiting TipRanks.

[object Object]
Preview
8.5
10-21NASDAQ.COM
Minerva Neurosciences Soars 339% Following $200M Financing Deal

  • Stock Surge: Minerva Neurosciences, Inc. (NERV) experienced a 339.33% increase in stock price, reaching $11.73 after announcing a $200 million financing deal for its schizophrenia drug candidate, roluperidone.

  • Financing Details: The financing agreement includes $80 million upfront, $80 million through Tranche A warrants, and $40 million via milestone-based Tranche B warrants to support a Phase 3 trial and potential U.S. commercial launch.

  • Trading Activity: On the day of the announcement, NERV opened at $3.02, peaked at $12.15, and had a trading volume exceeding 70 million shares, significantly higher than its average of 0.8 million.

  • Stock Performance: The stock's 52-week range is noted to be between $1.03 and $12.15, indicating significant volatility and investor interest.

[object Object]
Preview
8.5
10-21TipRanks
What’s Behind the 165% Surge in Minerva Neurosciences Stock (NERV) Today?

  • Stock Surge: Minerva Neurosciences (NERV) stock soared 163.16% in pre-market trading after announcing a $200 million securities purchase agreement with institutional investors, including $80 million in upfront funding.

  • Funding Purpose: The company plans to use the proceeds to advance its research and development of roluperidone, a treatment for schizophrenia, including a confirmatory Phase 3 trial and preparation for a New Drug Application resubmission.

  • CEO Statement: Dr. Remy Luthringer emphasized the company's commitment to successfully executing the trial to demonstrate the effectiveness of roluperidone in treating negative symptoms of schizophrenia.

  • Analyst Coverage: Despite the stock's rise, analyst coverage is limited, with TipRanks’ AI analyst rating NERV stock as Underperform due to concerns over financial instability and lack of revenue.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Minerva Neurosciences Inc (NERV) stock price today?

The current price of NERV is 3.74 USD — it has increased 12.31 % in the last trading day.

arrow icon

What is Minerva Neurosciences Inc (NERV)'s business?

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development and commercialization of proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company is involved in developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop and commercialize MIN-301 for the treatment of Parkinson’s disease. It has also co-developed seltorexant for the treatment of insomnia disorder and adjunctive treatment of major depressive disorder (MDD). Seltorexant is an innovative selective orexin 2 receptor antagonist. Its Roluperidone is a compound that has been shown to block serotonin, sigma, and α-adrenergic receptors that are involved in the regulation of mood, cognition, sleep and anxiety. Roluperidone has been designed to block a specific subtype of serotonin receptor called 5-HT2A.

arrow icon

What is the price predicton of NERV Stock?

Wall Street analysts forecast NERV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NERV is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Minerva Neurosciences Inc (NERV)'s revenue for the last quarter?

Minerva Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Minerva Neurosciences Inc (NERV)'s earnings per share (EPS) for the last quarter?

Minerva Neurosciences Inc. EPS for the last quarter amounts to -0.36 USD, decreased -112.12 % YoY.

arrow icon

What changes have occurred in the market's expectations for Minerva Neurosciences Inc (NERV)'s fundamentals?

The market is revising No Change the revenue expectations for Minerva Neurosciences, Inc. (NERV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 59.15%.
arrow icon

How many employees does Minerva Neurosciences Inc (NERV). have?

Minerva Neurosciences Inc (NERV) has 8 emplpoyees as of December 05 2025.

arrow icon

What is Minerva Neurosciences Inc (NERV) market cap?

Today NERV has the market capitalization of 26.16M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free